

Amendment

The following listing of claims will replace all prior versions and listings of claims in the application.


Listing of the Claims:

1-12. (Canceled)

13. (Currently Amended) A vaccine for preventing infections with influenza virus comprising:

an influenza virus antigen;

a peptide (Peptide A) comprising a sequence R_1 -~~XZZXZ_NXZX~~- R_2 , whereby N is a whole number between 3 and 7, X is a positively charged natural and/or non-natural amino acid residue, Z is an amino acid residue selected from the group consisting of L, V, I, F and/or W, and R_1 and R_2 are independently H, NH_2 , $COCH_3$, COH , a peptide with up to 20 amino acid residues or a peptide reactive group or a peptide linker with or without a peptide; ~~X- R_2 is an amide, ester or thioester of the C-terminal amino acid residue of the peptide KLKL₅KLK (SEQ ID NO:6); and~~
an immunostimulatory oligodeoxynucleic acid molecule (I-/U-ODN), wherein the I-/U-ODN comprises oligo d(IC)₁₃, I-ODN2, or I-ODN2b, having the structure according to the formula (I):



wherein:

~~R1 is selected from hypoxanthine and uracile;~~

~~any X is O or S;~~

~~any NMP is a 2' deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine, deoxyguanosine, deoxyinosine, deoxycytosine, deoxyuridine, deoxythymidine, 2-methyl deoxyinosine, 5-methyl deoxycytosine, deoxypseudouridine, deoxyribosepurine, 2-amino deoxyribosepurine, 6-S deoxyguanine, 2-dimethyl deoxyguanosine or N-isopentenyl deoxyadenosine monophosphate or monothiophosphate;~~

~~NUC is a 2' deoxynucleoside, selected from the group consisting of deoxyadenosine, deoxyguanosine, deoxyinosine, deoxycytosine, deoxyinosine, deoxythymidine, 2-methyl deoxyuridine, 5-methyl deoxycytosine, deoxypseudouridine, deoxyribosepurine, 2-amino deoxyribosepurine, 6-S deoxyguanine, 2-dimethyl deoxyguanosine or N-isopentenyl deoxyadenosine;~~

~~a and b are integers from 0 to 100 with the proviso that a + b is between 4 and 150; and~~

~~B and E are common groups for 5' or 3' ends of nucleic acid molecules.~~

14. (Canceled)

15. (Previously Presented) The vaccine of claim 13, further comprising an $\text{Al}(\text{OH})_3$ adjuvant.

16-17. (Canceled)

18. (Previously Presented) The vaccine of claim 13, wherein the influenza antigen is a haemagglutinin antigen or a neuraminidase antigen.

19. (Previously Presented) The vaccine of claim 13, further comprising a polycationic peptide.

20. (Currently Amended) The vaccine of claim 13, wherein ~~Peptide A is KLKL₅KLK (SEQ ID NO:6)~~ and the I/U-ODN is oligo d(IC)₁₃.

21. (Previously Presented) The vaccine of claim 13, further comprising an oligodeoxynucleotide containing a CpG-motif.

22. (Previously Presented) The vaccine of claim 13, further comprising a polycationic peptide and an oligodeoxynucleotide containing a CpG-motif.

23-28. (Canceled)

29. (New) The vaccine of claim 13, wherein the I/U-ODN is I-ODN2.

30. (New) The vaccine of claim 13, wherein the I/U-ODN is I-ODN2b.